Antibody–Invertase Fusion Protein Enables Quantitative Detection of SARS-CoV-2 Antibodies Using Widely Available Glucometers
Open Access
- 8 June 2022
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 144 (25) , 11226-11237
Abstract
Rapid diagnostics that can accurately inform patients of disease risk and protection are critical to mitigating the spread of the current COVID-19 pandemic and future infectious disease outbreaks. To be effective, such diagnostics must rely on simple, cost-effective, and widely available equipment and should be compatible with existing telehealth infrastructure to facilitate data access and remote care. Commercial glucometers are an established detection technology that can overcome the cost, time, and trained personnel requirements of current benchtop-based antibody serology assays when paired with reporter molecules that catalyze glucose conversion. To this end, we developed an enzymatic reporter that, when bound to disease-specific patient antibodies, produces glucose in proportion to the level of antibodies present in the patient sample. Although a straightforward concept, the coupling of enzymatic reporters to secondary antibodies or antigens often results in low yields, indeterminant stoichiometry, reduced target binding, and poor catalytic efficiency. Our enzymatic reporter is a novel fusion protein that comprises an antihuman immunoglobulin G (IgG) antibody genetically fused to two invertase molecules. The resulting fusion protein retains the binding affinity and catalytic activity of the constituent proteins and serves as an accurate reporter for immunoassays. Using this fusion, we demonstrate quantitative glucometer-based measurement of anti-SARS-CoV-2 spike protein antibodies in blinded clinical sample training sets. Our results demonstrate the ability to detect SARS-CoV-2-specific IgGs in patient serum with precise agreement to benchmark commercial immunoassays. Because our fusion protein binds all human IgG isotypes, it represents a versatile tool for detection of disease-specific antibodies in a broad range of biomedical applications.Keywords
Funding Information
- Emerson Collective
- Johns Hopkins Hospital
- Johns Hopkins University
- National Institute of General Medical Sciences (K12 GM123914)
This publication has 47 references indexed in Scilit:
- Expression of an antibody-enzyme complex by the L-chain fusion methodJournal of Bioscience and Bioengineering, 2013
- Portable and Quantitative Detection of Protein Biomarkers and Small Molecular Toxins Using Antibodies and Ubiquitous Personal Glucose MetersAnalytical Chemistry, 2012
- Using personal glucose meters and functional DNA sensors to quantify a variety of analytical targetsNature Chemistry, 2011
- Expression of antibody variable region-human alkaline phosphatase fusion proteins in mammalian cellsJournal of Immunological Methods, 2010
- The agreement chart as an alternative to the receiver-operating characteristic curve for diagnostic testsJournal of Clinical Epidemiology, 2008
- Bifunctional antibody-Renilla luciferase fusion protein for in vivo optical detection of tumorsProtein Engineering, Design and Selection, 2006
- Immunoenzymometric Assay for a Small Molecule,11-Deoxycortisol, with Attomole-Range Sensitivity Employing an scFv−Enzyme Fusion Protein and Anti-Idiotype AntibodiesAnalytical Chemistry, 2006
- Purification and characterization of an invertase from Candida utilis: comparison with natural and recombinant yeast invertasesJournal of Biotechnology, 1997
- Which of the commonly used marker enzymes gives the best results in colorimetric and fluorimetric enzyme immunoassays: Horseradish peroxidase, alkaline phosphatase or β-galactosidase?Journal of Immunological Methods, 1985
- Evaluation of Thirty-One Mouse Monoclonal Antibodies to Human IgG EpitopesHybridoma, 1984